Praxis Precision Medicine Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines, Inc. FDA has set a PDUFA target date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Praxis Precision MedicineInc. (NASDAQ: PRAX), a fully integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has accepted for priority review its New … Read more
